Guidance Capital Inc. Acquires 1,284 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Guidance Capital Inc. raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 54.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,642 shares of the company’s stock after acquiring an additional 1,284 shares during the period. Guidance Capital Inc.’s holdings in TransMedics Group were worth $222,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Geode Capital Management LLC grew its position in TransMedics Group by 1.3% during the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after acquiring an additional 10,106 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in TransMedics Group by 5.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after acquiring an additional 30,092 shares during the last quarter. Vaughan Nelson Investment Management L.P. grew its position in TransMedics Group by 24.3% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after acquiring an additional 64,360 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after acquiring an additional 6,634 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after acquiring an additional 146,115 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.00% of the company’s stock.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $74.57 on Thursday. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market capitalization of $2.50 billion, a P/E ratio of 79.33 and a beta of 2.12. The business has a fifty day simple moving average of $66.92 and a two-hundred day simple moving average of $110.67. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Canaccord Genuity Group reduced their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Piper Sandler cut their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Robert W. Baird dropped their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, TransMedics Group presently has an average rating of “Moderate Buy” and an average price target of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.